Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755117 | 0.88 | BRD4 (0.49) | ALDH1A1ALPLPDE3BPDE3APOLB | |
| SCHEMBL6246134 | 0.84 | PDE3B (0.42) | ALDH1A1KDM4ESMN1; SMN2ALPLPDE3B | |
| SCHEMBL1744525 | 0.83 | PGR (0.43) | ALDH1A1ALPLPOLBAKR1B1CAPN9 | |
| SCHEMBL3715441 | 0.83 | ALPL (0.48) | ALDH1A1ALPLPOLBAKR1B1CAPN9 | |
| SCHEMBL13007730 | 0.82 | ALPL (0.47) | ALDH1A1ALPLPOLBAKR1B1CAPN9 | |
| SCHEMBL8634618 | 0.81 | NPC1 (0.46) | ALDH1A1KDM4ESMN1; SMN2ALPLPOLB | |
| SCHEMBL13253436 | 0.80 | ALPL (0.48) | ALDH1A1ALPLPOLBAKR1B1CAPN9 | |
| SCHEMBL8800996 | 0.80 | ALPL (0.45) | ALDH1A1KDM4ESMN1; SMN2ALPLPOLB | |
| SCHEMBL8799897 | 0.80 | ALPL (0.45) | ALDH1A1ALPLPOLBAKR1B1CAPN9 | |
| SCHEMBL15212007 | 0.79 | ALPL (0.43) | ALDH1A1KDM4ESMN1; SMN2ALPLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| EP-2833889-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2833889-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| US-5420126-A | Potassium channel activators | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0432893-A2 | Benzoxazine derivatives, their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | ALDH1A1 389/4885KDM4E 922/4885SMN1; SMN2 1447/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | ALDH1A1 261/4885KDM4E 1133/4885SMN1; SMN2 2090/4885 |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885KDM4E 2813/4885SMN1; SMN2 1709/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | ALDH1A1 178/4885KDM4E 1056/4885SMN1; SMN2 2424/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | ALDH1A1 192/4885KDM4E 850/4885SMN1; SMN2 1788/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | ALDH1A1 178/4885KDM4E 1056/4885SMN1; SMN2 2424/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | ALDH1A1 192/4885KDM4E 850/4885SMN1; SMN2 1788/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885KDM4E 2813/4885SMN1; SMN2 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.